Objectives: Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little activity against the emerging pathogen Mycobacterium abscessus. Reportedly, bacterial resistance to rifampicin is associated with polymorphisms in the target gene rpoB or the presence of enzymes that modify and thereby inactivate rifampicin. The aim of this study was to investigate the role of the MAB_0591 (arr Mab )-encoded rifampicin ADPribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance in M. abscessus.
Introduction
Mycobacterium abscessus, an environmental saprophyte, is one of the most pathogenic and drug-resistant organisms among rapidly growing mycobacteria (RGM). 1, 2 It accounts for $80% of all lung infections due to RGM, particularly exacerbations of chronic lung disease in patients with cystic fibrosis or bronchiectasis. M. abscessus is also responsible for skin or soft tissue infections, usually following trauma, plastic surgery or aesthetic procedures (tattooing and body piercing). [3] [4] [5] [6] [7] [8] [9] [10] [11] Currently, there is no reliable antibiotic regimen for the treatment of infections with M. abscessus, as this bacterium demonstrates a high level of intrinsic and acquired resistance to commonly administered antibiotics. 2, 3, 7, 11 Rifampicin is a major chemotherapeutic agent of the rifamycin group. 12, 13 The rifampicin mechanism of action is based on its ability to inhibit transcription by binding with high affinity to the rpoBencoded b-subunit (RpoB) of the DNA-dependent RNA polymerase of prokaryotes. 14, 15 Bacterial rifampicin resistance is mostly attributed to alterations in rpoB, responsible for decreased affinity of the RpoB for rifampicin. [15] [16] [17] [18] Less frequent mechanisms of rifampicin resistance include limited membrane permeability to rifampicin and enzymatic inactivation of rifampicin through modification processes. [19] [20] [21] [22] [23] [24] Rifampicin resistance mutations were originally identified and extensively studied in Escherichia coli and are mapped in four distinct sequence clusters within the rpoB gene, known as the N-terminal cluster (N) and clusters I, II and III. [25] [26] [27] [28] [29] [30] It has subsequently been shown that the majority of rifampicin resistance mutations occur within an 81 bp region of cluster I, denoted as the rifampicin resistance-determining region, across all bacterial species. 28, [31] [32] [33] In Mycobacterium tuberculosis, high-level clinically acquired rifampicin resistance is almost always conferred by mutations in rpoB. 34 In contrast, Mycobacterium smegmatis, which is naturally resistant to rifampicin, has rifampicin ADP-ribosyltransferase activity conferring innate rifampicin resistance. 22, 35, 36 Combrink et al.
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V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com delineated that the mechanism of Arr_Msm-mediated rifampicin inactivation can be overcome by a series of 3-morpholino rifamycins in which the C25 acetate group of the rifamycin core was replaced by a bulky carbamate group. The C25 carbamate prevents ribosylation of the adjacent C23 alcohol catalysed by Arr_Msm and thus C25 rifamycins exhibit improved antimicrobial activity compared with rifampicin against M. smegmatis.
WGS revealed that M. abscessus carries a putative ADPribosyltransferase (Arr_Mab), encoded by MAB_0591 (arr Mab ). 11, 38 To date, no experimental data have defined the exact function of MAB_0591 nor confirmed its association with M. abscessus innate high-level rifampicin resistance.
We here used heterologous expression of MAB_0591 and targeted deletion of MAB_0591 in M. abscessus to identify Arr_Mab as the major relevant rifampicin resistance determinant in the type strain M. abscessus ATCC 19977. In addition, our finding that Arr_Mab-mediated rifampicin resistance in M. abscessus can hardly be overcome by rifamycin C25 carbamate modification has important consequences for the development of new rifamycin derivatives active against M. abscessus.
Materials and methods

RpoB amino acid sequence alignment
The RpoB sequences of E. coli K-12, M. tuberculosis H37Rv, M. smegmatis mc 2 155 and M. abscessus ATCC 19977 were collected from the National Center for Biotechnology Information (NCBI) database (http://www.ncbi. nlm.nih.gov/protein/). Multiple sequence alignment was performed using the ClustalW2 program (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Bacterial strains and growing conditions
(i) E. coli strains were cultivated in LB medium at 37 C overnight. Ampicillin was added to the medium at a final concentration of 120 mg/L when necessary. For all cloning steps, E. coli XL1-Blue or E. coli MC1061 were used, whereas the E. coli-gfp control strain and E. coli-arr Mab testing strain were used for MIC assays. (ii) M. abscessus strains were grown in Middlebrook 7H9 liquid medium or on LB agar plates at 37 C for 5 days. When needed, apramycin was added at a final concentration of 50 mg/L. The M. abscessus ATCC 19977 type strain, M. abscessus Darr Mab mutant strain, M. abscessus Darr Mab -arr Mab complemented mutant strain and M. abscessus Darr Mab pMV361-aac(3)IV vector backbone control strain were used throughout this study. (iii) The M. smegmatis mc 2 155 type strain was grown on LB agar plates at 37 C for 3 days. (iv) M. tuberculosis strains were cultivated in Middlebrook 7H9 liquid medium or on Middlebrook 7H10 agar plates at 37 C for 2-4 weeks and apramycin was added at a final concentration of 50 mg/L when necessary. The M. tuberculosis H37Rv type strain, Mtbaac(3)IV control strain and Mtb-aac(3)IV-arr Mab testing strain were used in this study.
Antibiotics
Ampicillin, apramycin, amikacin, isoniazid, rifampicin, rifapentine and rifaximin were bought from Sigma-Aldrich, Switzerland. The following C25 modified rifamycin derivatives were synthesized according to the literature protocol: 37 . Following initial cloning into the pINIT vector, the sequence-verified MAB_0591 amplicon was inserted downstream of the arabinose-inducible pBAD promoter into the multicopy expression vector pBXNH3 via a fragment exchange cloning system. 39 The resulting E. coli MC1061 pBXNH3-arr Mab testing strain is referred to as E. coliarr Mab . As a control, gfp was amplified from the pOLYG-gfp-hyg vector (5 0 -ATATATGCTCTTCTAGTATCTCGAAGGGCGAGGAGCT-3 0 and 5 0 -TATATA GCTCTTCATGCCTTGTACAGCTCGTCCATGCCG-3 0 ) and cloned directly into the pBXNH3 expression vector. The resulting E. coli MC1061 pBXNH3-gfp control strain expressing gfp is referred to as E. coli-gfp. Gene expression of MAB_0591 and gfp was conducted by induction of 30 mL bacterial cultures (OD 600 ¼ 0.85-1) with L-arabinose at a final concentration of 0.2% v/v, at 37 C for 4.5 h.
Expression of MAB_0591 in M. tuberculosis
MAB_0591 (including its native promoter) was PCR amplified from M. abscessus ATCC 19977 genomic DNA using KpnI-linker modified primers 5 0 -AGGGTACCCGGATATGTGCAGCGGCATG-3 0 and 5 0 -GAGGTACCCACCGAAG CACTGAAGGTGC-3 0 and cloned into the KpnI site of the pMV361-aac(3)IV vector to result in the pMV361-aac(3)IV-MAB_0591 complementing vector. The control backbone vector [pMV361-aac(3)IV] and the complementing vector [pMV361-aac(3)IV-MAB_0591] were transformed into the electrocompetent M. tuberculosis H37Rv type strain, as previously described for Mycobacterium bovis BCG. 40 Briefly, 400 lL of M. tuberculosis H37Rv competent cells were mixed with 1 lg of supercoiled plasmid DNA and electroporated in a Bio-Rad Gene Pulser II (settings: 2.5 kV, 1000 Ohms and 25 lF). Following electroporation, cells were resuspended in 4 mL of 7H9-OADCTween 80 and incubated for 20 h at 37 C. Appropriate dilutions were plated on selective agar and after 3 weeks of incubation, single colonies were picked, restreaked and grown in liquid broth when necessary. The Mtbaac(3)IV control strain and the Mtb-aac(3)IV-arr Mab testing strain were obtained by positive selection on 7H10 plates containing apramycin. The presence of the aac(3)IV and/or the MAB_0591 gene(s) in these strains was confirmed by colony PCR.
Deletion of MAB_0591 in M. abscessus 
, respectively)] and stepwise cloned into the pSE-katG-aac(3)IV suicide vector resulting in the knockout vector pSE-katG-aac(3)IV-DMAB_0591. Details on the construction of the M. abscessus deletion mutant will be described elsewhere (A. Rominski, P. Selchow and P. Sander, unpublished results). Briefly, pSE-katG-aac(3)IV-DMAB_0591 was transformed into electrocompetent M. abscessus ATCC 19977. For electroporation, 100 lL of competent cells were mixed with 1-2 lg of supercoiled plasmid DNA and electroporated in a Bio-Rad Gene Pulser II (settings: 2.5 kV, 1000 Ohms and 25 lF). After electroporation, cells were resuspended in 0.9 mL of 7H9 medium and incubated for 5 h with constant shaking (1000 rpm) at 37 C. Appropriate dilutions were subsequently plated on selective agar and after 5 days of incubation, single colonies were picked, restreaked and grown in liquid broth when necessary.
Rifamycin resistance mechanisms of Mycobacterium abscessus JAC Transformants were selected on LB agar plates containing apramycin and identified by aac(3)IV PCR. Single crossover transformants were identified by Southern blot analysis with a 0.2 kbp EcoRI 5 0 arr Mab DNA probe (the same probe was also used for all subsequent Southern blot analyses) and subjected to counterselection on LB agar plates containing isoniazid (32 mg/L). Single colonies were screened for deletion of MAB_0591 by PCR and the genotype was finally confirmed by Southern blot analysis. In this way, a 0.3 kbp region of the MAB_0591 was deleted. For complementation of the M. abscessus Darr Mab mutant with MAB_0591, the previously described complementation vector pMV361-aac(3)IV-MAB_0591 was transformed into the Darr Mab mutant strain. Transformation was verified by Southern blot analysis.
Susceptibility testing of M. tuberculosis strains
Drug susceptibility testing (DST) was performed using the MGIT 960 system as recommended by the manufacturer 41 and the results were interpreted as described previously by Springer et al. 42 Briefly, 0.5 mL dilutions of positive MGIT vials of the Mtb-aac(3)IV control strain and the Mtb-aac(3)IVarr Mab testing strain were inoculated into fresh vials containing constant levels of apramycin for plasmid maintenance and different concentrations of the test drugs. 43 Rifampicin was tested at concentrations of 1, 4 and 20 mg/L, while the control drug isoniazid was tested at concentrations of 0.1, 1, 3 and 10 mg/L. For the drug-free growth control, the bacterial working suspension was diluted 1:100 with sterile NaCl and 0.5 mL of the diluted working suspension was inoculated into the tube (proportion testing). 44 All MGIT tubes were incubated in the MGIT 960 instrument and monitored using EpiCenter (version 5.53) software equipped with the TB eXiST module (Becton Dickinson).
Rifampicin Etest
Bacterial suspensions of M. abscessus strains ATCC 19977, Darr Mab and Darr Mab -arr Mab were adjusted to a turbidity equivalent to that of a 0. 50 McFarland standard and subsequently spread on LB agar plates using a sterile cotton swab. Then, a rifampicin Etest strip (bioMérieux, Switzerland) was placed on each plate and plates were incubated for 5 days at 37 C. The point of intersection between bacterial growth and the Etest device was read as the MIC value.
MIC assays
MIC assays were performed according to CLSI guidelines. 45 Working solutions were prepared by diluting the antibiotic stock solutions in CAMHB (pH 7.4) (Becton Dickinson, Switzerland) to a concentration corresponding to twice the desired final concentration [working solutions of 128, 512 and 1024 mg/L were prepared when the highest concentrations tested in the MIC assay were 64, 256 and 512 mg/L, respectively (Table 1 and Table 3) ]. By using CAMHB in sterile 96-well microtitre plates (Greiner Bio-One, Switzerland), 2-fold serial dilutions of the working solutions were prepared. A positive growth control lacking antibiotic and a sterile negative control containing only CAMHB were included in each 96-well microtitre plate. For the preparation of the inoculum, three to four colonies from each bacterial strain grown on LB agar were transferred into a glass tube containing 2 mL of NaCl using a sterile cotton swab. In order to achieve a final inoculum titre of 1-5 Â 10 5 cfu/mL, all bacterial suspensions were adjusted to a turbidity equivalent to that of a 0.50 McFarland standard and subsequently diluted in CAMHB. The final test volume in each well of the microtitre plate was 0.1 mL. The correct titre of each inoculum was checked by obtaining cfu counts on LB agar plates. All microdilution plates were capped with adhesive sealing covers and incubated at 37 C for (i) 16 h for E. coli strains and (ii) 3, 5, 7 and 12 days for M. abscessus and M. smegmatis strains, before the MIC values were assessed by visual inspection. All MIC assays were conducted in triplicate.
Results and discussion
Analysis of the RpoB rifampicin resistance sequence clusters from M. abscessus
To investigate whether innate rifampicin resistance in M. abscessus (MIC: 128 mg/L) is associated with polymorphisms in the RNA polymerase b-subunit, we aligned the RpoB amino acid sequence of M. abscessus ATCC 19977 with those of E. coli K-12 and M. tuberculosis H37Rv, known to be naturally susceptible to rifampicin, 13, 16 and M. smegmatis mc 2 155 that has no polymorphism in its rpoB gene corresponding to any known rifampicin resistance genotype, 35 but is naturally resistant to rifampicin through ADP-ribosylation of rifampicin. 22, 36 Our analysis revealed no polymorphism known to confer rifampicin resistance within all four (N, I, II and III) rifampicin resistance sequence clusters of M. abscessus RpoB (Figure 1 ), suggesting that other mechanisms are involved in the high intrinsic rifampicin resistance of M. abscessus. Possible mechanisms include efflux of rifampicin, diminished uptake of rifampicin and enzymatic degradation or modification of rifampicin. [19] [20] [21] [22] [23] The latter resistance mechanism has been studied in M. smegmatis and Legionella pneumophila. 22, 23 A recent genome analysis suggested that M. abscessus carries a putative rifampicin ADPribosyltransferase (Arr_Mab), 38 encoded by MAB_0591 (arr Mab ). MAB_0591 has 66% amino acid sequence identity with the M. smegmatis ADP-ribosyltransferase that modifies rifampicin. However, Table S1 (available as Supplementary data at JAC Online), which lists the MIC values for selected mycobacterial standard strains 42, 46, 47 as well as information about the presence or absence of ADP-ribosyltransferase-like protein in these species, shows that a direct correlation between rifampicin MIC and the presence or absence of ADP-ribosyltransferase-like proteins does not exist. M. tuberculosis and Mycobacterium leprae were predicted to have no ADP-ribosyltransferase-like proteins and are susceptible to rifampicin (MIC: <1 mg/L). 42, 47 ADP-ribosyltransferases were predicted to be present in M. abscessus (M. abscessus subsp. abscessus and M. abscessus subsp. bolletii) and Mycobacterium fortuitum and these species are resistant (MIC: !64 mg/L). 46 In contrast, the presence of putative ADP-ribosyltransferases in e.g. Mycobacteriumphlei, Mycobacterium gilvum and Mycobacterium marinum does not correlate with high rifampicin MIC levels (MIC: <0.5 mg/L). 46 Therefore, a functional role of ADPribosyltransferases in rifampicin resistance has to be addressed experimentally. By using ADP-ribosyltransferase of M. smegmatis mc 2 155 in a BLASTP search, we identified also other, nonmycobacterial species predicted to possess ADPribosyltransferase-like proteins (Table S2) . Interestingly, mycobacterial ADP-ribosyltransferases show homology to the catalytic domain of exotoxin A from Pseudomonas aeruginosa, 48, 49 
Heterologous expression of MAB_0591 in E. coli and M. tuberculosis
To study if rifampicin resistance in M. abscessus is due to arr Mab , we cloned MAB_0591 and expressed the recombinant protein in two rifampicin-susceptible hosts, E. coli 16 and M. tuberculosis. 50 First, we addressed the question whether induced expression of MAB_0591 would confer rifampicin resistance in a non-mycobacterial heterologous host. Arr_Mab was recombinantly expressed by the multicopy pBXNH3-arr Mab vector in E. coli MC1061 under the control of the L-arabinose-inducible pBAD promoter. The E. coli-gfp control strain and the E. coli-arr Mab testing strain were generated following transformation with the pBXNH3-gfp and pBXNH3-arr Mab vectors, respectively. The recombinant strains were subsequently tested [24] [25] [26] [27] [28] [29] [30] Directly below follows the amino acid sequence alignment spanning the rifampicin resistance regions of E. coli K-12, M. tuberculosis H37Rv, M. smegmatis mc 2 155 and M. abscessus ATCC 19977 RpoB. Amino acid substitutions that confer rifampicin resistance are shown as coloured triangles above and below the alignment, respectively. The possible substitutions for each position are mentioned in single amino acid code in columns directly above (for E. coli) or below the coloured triangles (for M. tuberculosis). The yellow triangles represent the residues that interact directly with rifampicin binding. In contrast, the red triangles indicate residues that are positioned too far away to have direct interaction with rifampicin. The blue triangles show the positions that are substituted with the highest frequency among M. tuberculosis rifampicin-resistant isolates. 31 The green triangles show a residue that is directly interacting with rifampicin, but no substitutions have been reported at this position, probably because they would be fatal for the bacterium. 15 (b) Using the same colour code for the amino acid positions as above, the residues of direct interaction with rifampicin are shown (yellow, blue and green triangles). Hydrogen bonds formed between an RpoB residue and rifampicin are depicted as broken lines and residues that form van der Waals interactions are indicated in zigzag circles. Numbering of the residues is according to E. coli positions. 15 RIF, rifampicin. Rominski et al.
against rifampicin in MIC assays. The E. coli-arr Mab testing strain was highly resistant to rifampicin with MIC values >512 mg/L, while the E. coli-gfp control strain remained susceptible to rifampicin (MIC: 4 mg/L) ( Table 1 ). These results confirm that Arr_Mab plays a critical role as a rifampicin resistance determinant when expressed in the rifampicin-susceptible E. coli host. We hypothesize that Arr_Mab modifies rifampicin by ADP-ribosylation at the hydroxyl group of C23, as previously shown for Arr_Msm, 48 and that this modification interferes with target binding.
Next, we studied whether arr Mab confers rifampicin resistance in a mycobacterial host, M. tuberculosis. In order to simulate veritable levels of Arr_Mab expression, we expressed MAB_0591 under control of its native promoter. The single-copy integrating plasmids pMV361-aac(3)IV and pMV361-aac(3)IV-MAB_0591 were engineered and transformed into the rifampicin-susceptible M. tuberculosis H37Rv strain (MIC: <1 mg/L). 42 The aac(3)IV gene that confers resistance to apramycin was used as a positive selection marker. The resulting strains referred to as Mtb-aac(3)IV control strain and Mtb-aac(3)IV-arr Mab testing strain, respectively, were subjected to DST using the MGIT 960 system equipped with EpiCenter TB eXiST software. Susceptibility to different concentrations of rifampicin (1, 4 and 20 mg/L) and the non-substrate control drug isoniazid (0.1, 1, 3 and 10 mg/L) was determined. The Mtb-aac(3)IV control strain was, as expected, susceptible to both rifampicin and isoniazid at all concentrations tested (MIC: rifampicin <1.0 mg/L; isoniazid <0.1 mg/L). In contrast, the Mtb-aac(3)IV-arr Mab testing strain was specifically resistant to rifampicin, even at the highest concentration tested (MIC: >20 mg/L), but remained susceptible to the unrelated control drug isoniazid (MIC: <0.1 mg/L) ( Table 2 ). These findings demonstrate that MAB_0591 confers high-level resistance Rifamycin resistance mechanisms of Mycobacterium abscessus JAC to rifampicin, but not to other drugs, when expressed in a rifampicin-susceptible mycobacterial host.
Generation of M. abscessus MAB_0591 deletion mutant
Heterologous expression of MAB_0591 indicated that arr Mab is able to confer rifampicin resistance to a susceptible host; however, its role in innate rifampicin resistance in M. abscessus remained to be determined. We recently developed tools for genetic manipulation of M. abscessus (A. Rominski, P. Selchow and P. Sander, unpublished results) and wished to exploit this technique to generate an M. abscessus MAB_0591 deletion mutant. This mutant would allow us to directly address the role of MAB_0591 in innate rifampicin resistance. The arr Mab deletion mutant was constructed by transformation of M. abscessus ATCC 19977 with suicide plasmid pSEkatG-aac(3)IV-DMAB_0591 applying apramycin positive selection 51 and a katG-dependent isoniazid counterselection strategy that we previously established (A. Rominski, P. Selchow and P. Rominski et al.
DST of M. abscessus DMAB_0591
Arr_Mab (Table 3) . Transformation of the M. abscessus Darr Mab mutant with arr Mab restored WT levels of rifamycin resistance while transformation with the empty vector backbone did not. Expectedly, amikacin MICs were independent of the arr genotype. These findings identify Arr_Mab as the major rifamycin resistance determinant in M. abscessus.
DST of C25 modified rifamycin derivatives
Carbamate modification at the C25 position of the rifamycin core has been shown to improve antimicrobial activity against M. smegmatis mc 2 155. 37 We wanted to test whether these compounds also overcome rifamycin resistance in M. abscessus. C25 modified rifamycin derivatives 5f, 5k and 5l ( Figure 4) were custom synthesized and tested for antimicrobial activity. The compounds showed potent activity against M. smegmatis-on average these compounds were 100-200-fold more active than rifampicin. These results confirm former findings that C25 modified rifamycins apparently are resilient to modification by Arr_Msm. The C25 modified rifamycins also showed increased activity in M. abscessus as compared with rifampicin, rifapentine and rifaximin (Table 3) . Of note, C25 modification not only increases rifamycin activity against the M. abscessus WT, but also against the M. abscessus Darr Mab mutant, although to a lesser extent. These data indicate that the increased activity of C25 rifamycin derivatives is only partially due to resilience to Arr_Mab modification. Compared with compounds 5f and 5k, we observed little time-dependent increase in the MIC values of compound 5l for WT M. abscessus and the M. abscessus Darr Mab -arr Mab complemented mutant, indicating that 5l is probably least modified by Arr_Mab, but still WT MIC values are high (4 mg/L; 16-fold higher than against the Darr Mab mutant).
Conclusions
Taken together, our study identified Arr_Mab as the major determinant of innate rifamycin resistance in M. abscessus. Our data indicate significant species-specific differences in rifamycin C25-mediated resilience for Arr_Msm and Arr_Mab, since Arr_Mab-mediated rifamycin resistance can only partly be overcome by C25 modification. These findings testify to the need to develop novel compounds that are able to escape Arr_Mab-mediated rifamycin resistance in M. abscessus. Structural similarity between Arr_Msm and protein ADP-ribosyltransferases, prominently domain III of P. aeruginosa exotoxin A, have been described. 48, 49 These structural features are also conserved in Arr_Mab. Therefore, it is tempting to speculate on a dual role of Arr_Mab in drug resistance and virulence.
